Alpha 2.0
Login Register
» Authors » E Mervaala

E Mervaala

Explore the profile of E Mervaala including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 99
Citations 1439
Followers 0
Related Specialties
Neurology
General Medicine
Cardiology & Vascular Diseases
Top 10 Co-Authors
J Partanen
U Nousiainen
P RIEKKINEN
R Kalviainen
H Karppanen
A Ylinen
M Vapalahti
H Vapaatalo
A Tuunainen
P Tiihonen
Published In
Duodecim
Epilepsia
Neurology
Arch Neurol
Blood Press
Affiliations
Soon will be listed here.
Recent Articles
1.
Altered acylcarnitine metabolism and inflexible mitochondrial fuel utilization characterize the loss of neonatal myocardial regeneration capacity
Kankuri E, Finckenberg P, Leinonen J, Tarkia M, Bjork S, Purhonen J, et al.
Exp Mol Med . 2023 Apr; 55(4):806-817. PMID: 37009793
Myocardial regeneration capacity declines during the first week after birth, and this decline is linked to adaptation to oxidative metabolism. Utilizing this regenerative window, we characterized the metabolic changes in...
2.
Decreased Gray-White Matter Contrast of [11C]-PiB Uptake in Cognitively Unimpaired Subjects with Severe Obstructive Sleep Apnea
Yla-Herttuala S, Hakulinen M, Poutiainen P, Lotjonen J, Kononen M, Grohn H, et al.
J Prev Alzheimers Dis . 2022 Jul; 9(3):499-506. PMID: 35841251
Background: Very recently, cognitively normal, middle-aged adults with severe obstructive sleep apnea (OSA) were shown to have regional cortical amyloid-β deposits. In the normal brain, amyloid tracer (e.g., [11C]-PiB) uptake...
3.
Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes
Nissinen T, Degerman J, Rasanen M, Poikonen A, Koskinen S, Mervaala E, et al.
Sci Rep . 2016 Sep; 6:32695. PMID: 27666826
Doxorubicin is a widely used and effective chemotherapy drug. However, cardiac and skeletal muscle toxicity of doxorubicin limits its use. Inhibiting myostatin/activin signalling can prevent muscle atrophy, but its effects...
4.
The effects of intravenous lipid emulsion on hemodynamic recovery and myocardial cell mitochondrial function after bupivacaine toxicity in anesthetized pigs
Heinonen J, Schramko A, Skrifvars M, Litonius E, Backman J, Mervaala E, et al.
Hum Exp Toxicol . 2016 May; 36(4):365-375. PMID: 27222493
Local anesthetic toxicity is thought to be mediated partly by inhibition of cardiac mitochondrial function. Intravenous (i.v.) lipid emulsion may overcome this energy depletion, but doses larger than currently recommended...
5.
Amount of weight loss or gain influences the severity of respiratory events in sleep apnea
Kulkas A, Leppanen T, Sahlman J, Tiihonen P, Mervaala E, Kokkarinen J, et al.
Med Biol Eng Comput . 2015 Apr; 53(10):975-88. PMID: 25894465
Severity of obstructive sleep apnea (OSA) is estimated based on respiratory events per hour [i.e., apnea-hypopnea index (AHI)]. The aim of this study was to investigate effects of weight change...
6.
Weight loss alters severity of individual nocturnal respiratory events depending on sleeping position
Kulkas A, Leppanen T, Sahlman J, Tiihonen P, Mervaala E, Kokkarinen J, et al.
Physiol Meas . 2014 Sep; 35(10):2037-52. PMID: 25237739
Weight loss is an effective treatment for obstructive sleep apnea (OSA). The mechanisms of how weight loss affects nocturnal breathing are not fully understood. The severity of OSA is currently...
7.
Adjustment of apnea-hypopnea index with severity of obstruction events enhances detection of sleep apnea patients with the highest risk of severe health consequences
Muraja-Murro A, Kulkas A, Hiltunen M, Kupari S, Hukkanen T, Tiihonen P, et al.
Sleep Breath . 2014 Jan; 18(3):641-7. PMID: 24390072
Introduction: Presently, the severity of obstructive sleep apnea (OSA) is estimated based on the apnea-hypopnea index (AHI). Unfortunately, AHI does not provide information on the severity of individual obstruction events....
8.
Novel parameters reflect changes in morphology of respiratory events during weight loss
Kulkas A, Leppanen T, Sahlman J, Tiihonen P, Mervaala E, Kokkarinen J, et al.
Physiol Meas . 2013 Aug; 34(9):1013-26. PMID: 23945509
Apnea-hypopnea-index (AHI), disregarding the respiratory event morphology, is currently used in estimation of severity of obstructive sleep apnea (OSA). The purpose of the current study was to evaluate the potential...
9.
Mortality in middle-aged men with obstructive sleep apnea in Finland
Muraja-Murro A, Eskola K, Kolari T, Tiihonen P, Hukkanen T, Tuomilehto H, et al.
Sleep Breath . 2013 Jan; 17(3):1047-53. PMID: 23361136
Introduction: Obstructive sleep apnea (OSA) has been associated with an elevated rate of cardiovascular mortality. However, this issue has not been investigated in patients with elevated proneness to cardiovascular diseases....
10.
Novel parameters for evaluating severity of sleep disordered breathing and for supporting diagnosis of sleep apnea-hypopnea syndrome
Kulkas A, Tiihonen P, Eskola K, Julkunen P, Mervaala E, Toyras J
J Med Eng Technol . 2013 Jan; 37(2):135-43. PMID: 23360196
Sleep apnea-hypopnea syndrome (SAHS) is a complex public health problem causing increased risk of cardiovascular diseases. Traditionally, evaluation of the severity of the disease is based on Apnea-Hypopnea Index (AHI)....